- Page 1 and 2: sociEtY FoR NEURosciENcE Program Mo
- Page 3 and 4: Monday Highlights ✍ Preregistrati
- Page 5 and 6: Chronological List of Monday Sessio
- Page 7 and 8: Session Number Theme Title Presenta
- Page 9 and 10: Session Number Theme Title Presenta
- Page 11 and 12: Session Number 511 F Theme Title Ex
- Page 13 and 14: Monday Socials 6:45 - 8:45 p.m. Alz
- Page 15: Monday Satellite Events & Non-SfN S
- Page 19 and 20: 9:35 314.05 The role of phase of fi
- Page 21 and 22: 9:45 320.08 Signs of time in tauopa
- Page 23 and 24: 9:45 324.08 • Category representa
- Page 25 and 26: 9:00 A11 329.02 Identification of F
- Page 27 and 28: 10:00 A55 331.07 Basolateral amygda
- Page 29 and 30: 11:00 B34 334.12 Fyn and cdk5 coord
- Page 31 and 32: 8:00 C18 336.17 Construction of cel
- Page 33 and 34: 10:00 D15 339.15 Elucidation of M 5
- Page 35 and 36: 9:00 D59 341.26 Advancing the rhesu
- Page 37 and 38: 8:00 E32 343.17 Ambient pressure io
- Page 39 and 40: 8:00 I12 345.13 � Peptidergic mod
- Page 41 and 42: 11:00 N6 348.04 � Sub-second indu
- Page 43 and 44: 11:00 S3 351.04 • Altered intrins
- Page 45 and 46: 11:00 X1 352.20 Investigating Alzhe
- Page 47 and 48: 8:00 Z2 354.21 BACE1 function in th
- Page 49 and 50: 9:00 AA11 356.10 BmDJ-1 is a key re
- Page 51 and 52: 11:00 BB14 358.04 Exercise is not b
- Page 53 and 54: 8:00 DD3 360.05 Digital analysis of
- Page 55 and 56: 9:00 EE10 362.10 • Valproic acid
- Page 57 and 58: 9:00 FF28 363.26 • Inhibition of
- Page 59 and 60: 10:00 HH2 366.03 Extracellular prog
- Page 61 and 62: 11:00 II17 368.08 Hippocampal forma
- Page 63 and 64: 11:00 JJ34 370.16 Audiovisual feedb
- Page 65 and 66: 9:00 LL9 372.10 • Participation o
- Page 67 and 68:
8:00 MM28 375.13 Analysis of the de
- Page 69 and 70:
8:00 OO12 378.09 The hemodynamic re
- Page 71 and 72:
9:00 QQ2 380.30 Gain of constitutiv
- Page 73 and 74:
11:00 RR13 382.24 Biphasic BOLD res
- Page 75 and 76:
11:00 SS25 385.04 Opposing catechol
- Page 77 and 78:
11:00 UU17 387.16 Reduced dimension
- Page 79 and 80:
8:00 VV27 390.05 Exposure to enviro
- Page 81 and 82:
9:00 VV77 392.18 Role of GPER1 in s
- Page 83 and 84:
9:00 WW26 395.06 Use of an in situ
- Page 85 and 86:
9:00 WW72 397.14 Prevention of CO 2
- Page 87 and 88:
9:00 XX50 399.26 • Silicon large-
- Page 89 and 90:
8:00 YY4 402.13 • Between-gender
- Page 91 and 92:
10:00 YY53 405.03 • Lost in trans
- Page 93 and 94:
10:00 ZZ11 407.15 � FVB mice show
- Page 95 and 96:
9:00 ZZ60 409.22 Increase of brain-
- Page 97 and 98:
10:00 AAA16 412.07 Repeated exposur
- Page 99 and 100:
ALBERT AND ELLEN GRASS LECTURE Walt
- Page 101 and 102:
NANOSYMPOSIUM 421. Synapse Formatio
- Page 103 and 104:
2:30 424.07 AAV2/5-mediated gene th
- Page 105 and 106:
1:45 429.04 Dark pulse-induced phas
- Page 107 and 108:
POSTER 434. Differentiation of Stem
- Page 109 and 110:
1:00 A60 436.09 Analysis in vitro o
- Page 111 and 112:
POSTER 439. Regeneration II Theme A
- Page 113 and 114:
1:00 C22 441.09 • Nicotine accele
- Page 115 and 116:
1:00 D19 444.05 D2 receptors regula
- Page 117 and 118:
1:00 D66 446.13 Packaging and physi
- Page 119 and 120:
1:00 G5 448.09 A study on the possi
- Page 121 and 122:
1:00 K11 451.05 Relationship betwee
- Page 123 and 124:
4:00 O11 453.12 • APP circadian r
- Page 125 and 126:
POSTER 456. Epilepsy and Neuronal N
- Page 127 and 128:
1:00 Y5 458.09 Abnormal expression
- Page 129 and 130:
4:00 Z11 460.16 Role of sodium/hydr
- Page 131 and 132:
3:00 AA16 462.23 Conditional SOX9 a
- Page 133 and 134:
4:00 CC1 465.04 • Treatment with
- Page 135 and 136:
4:00 DD11 467.12 • Increased expr
- Page 137 and 138:
POSTER 469. Alcohol: Behavioral Eff
- Page 139 and 140:
3:00 GG1 471.19 � Acute cocaine e
- Page 141 and 142:
POSTER 474. Serotonin, Histamine, a
- Page 143 and 144:
4:00 II27 476.04 Limbic markers of
- Page 145 and 146:
4:00 KK13 478.16 � Mapping ITD in
- Page 147 and 148:
2:00 LL30 481.14 Differential effec
- Page 149 and 150:
1:00 NN16 484.13 Low frequency loca
- Page 151 and 152:
2:00 OO32 487.02 Representation of
- Page 153 and 154:
3:00 QQ27 489.15 Visual and motor r
- Page 155 and 156:
2:00 SS1 493.10 Antinociceptive eff
- Page 157 and 158:
POSTER 496. Thalamocortical Process
- Page 159 and 160:
2:00 UU35 499.02 Astrocytes are sex
- Page 161 and 162:
3:00 VV45 502.03 Glial-neuronal int
- Page 163 and 164:
3:00 VV90 504.11 Prazosin injected
- Page 165 and 166:
4:00 WW42 507.04 GPR30 agonist impr
- Page 167 and 168:
3:00 XX20 509.03 A horse or an equi
- Page 169 and 170:
4:00 XX69 510.28 � Studies on alt
- Page 171 and 172:
3:00 YY28 512.27 Dopaminergic and g
- Page 173 and 174:
3:00 YY79 515.15 Neural activity in
- Page 175 and 176:
3:00 ZZ36 518.11 Analysis the effec
- Page 177 and 178:
3:00 ZZ84 520.07 Development of hyb
- Page 179 and 180:
ABSTRACT NUMBER STATEMENT Healthcar
- Page 181 and 182:
ABSTRACT NUMBER STATEMENT Employmen
- Page 183 and 184:
ABSTRACT NUMBER STATEMENT Research
- Page 185 and 186:
ABSTRACT NUMBER STATEMENT AstraZene
- Page 188 and 189:
Hotel Floor Plans Renaissance Washi
- Page 190 and 191:
Convention Center Floor Plans Conco
- Page 192 and 193:
Lobby Level/Level 1 & Meeting Rooms
- Page 194 and 195:
Level Two Exhibit Halls D & E Meeti
- Page 196 and 197:
Level Three Ballrooms A-C Meeting R
- Page 198 and 199:
1000 AISLE 1041 1039 1138 1025 111
- Page 200 and 201:
Notes
- Page 202:
sociEtY FoR NEURosciENcE Program Mo